Literature DB >> 2871107

Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.

A H Rook, J H Kehrl, L M Wakefield, A B Roberts, M B Sporn, D B Burlington, H C Lane, A S Fauci.   

Abstract

Type beta transforming growth factor (TGF-beta) is a unique polypeptide that has been isolated from a number of different tissues and can induce the phenotypic transformation of non-neoplastic fibroblasts as measured by the stimulation of their growth in soft agar. Recently, TGF-beta has been demonstrated to exert profound inhibitory effects on T and B lymphocyte proliferation. In this study, the effects of TGF-beta on natural killer (NK) cell function were investigated. After 20 hr of culture in the presence of TGF-beta, the NK activity of peripheral blood lymphocytes (PBL) was significantly reduced compared with PBL cultured in medium alone. Similarly, TGF-beta produced a significant depression in the cytolytic activity of highly enriched large granular lymphocytes (LGL). This effect of TGF-beta appeared to be mediated directly on the effector cells, because cultivation of the K562 target cells in TGF-beta did not affect target cell susceptibility to lysis. Binding studies with 125I-TGF-beta indicated that LGL possess approximately 1400 high-affinity (Kd = 1PM) receptors/cell, which represents a considerably higher affinity receptor for TGF-beta than that found on fibroblasts. Culturing of PBL and LGL in TGF-beta resulted in a marked blunting of the boosting of NK cytolysis by interferon-alpha but not by interleukin 2, which suggested that TGF-beta may down-regulate interferon-alpha receptors on NK cells. These results, indicate that in addition to inhibitory effects on T and B cells, TGF-beta also inhibits NK cell function. Although the in vivo role of TGF-beta is presently undefined, it may be an important immunoregulatory protein that has a negative influence on lymphocyte activation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2871107

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  147 in total

1.  Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.

Authors:  B Frankel; S L Longo; G W Canute
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  A phorbol ester-regulated ribonuclease system controlling transforming growth factor beta 1 gene expression in hematopoietic cells.

Authors:  R E Wager; R K Assoian
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

Review 3.  Lung cancer vaccines.

Authors:  Ronan J Kelly; Giuseppe Giaccone
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

4.  Regulation of clonal growth by anti-T-cell receptor antibody-directed lysis.

Authors:  P De Berardinis; M Londei; S Carrel; M Feldmann
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

5.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Inhibition of Nb2 T-lymphoma cell growth by transforming growth factor-beta.

Authors:  E J Rayhel; D A Prentice; P S Tabor; W H Flurkey; R W Geib; R F Laherty; S B Schnitzer; R Chen; J P Hughes
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

7.  Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.

Authors:  Roberta Castriconi; Claudia Cantoni; Mariella Della Chiesa; Massimo Vitale; Emanuela Marcenaro; Romana Conte; Roberto Biassoni; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-19       Impact factor: 11.205

8.  Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.

Authors:  Peter W Chen; Jessamee K Mellon; Elizabeth Mayhew; Shixuan Wang; Yu Guang He; Nick Hogan; Jerry Y Niederkorn
Journal:  Exp Eye Res       Date:  2007-07-25       Impact factor: 3.467

9.  Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease.

Authors:  M E Kadin; B A Agnarsson; L R Ellingsworth; S R Newcom
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

Review 10.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.